Alwin D. R. Huitema

18.0k total citations · 1 hit paper
552 papers, 12.9k citations indexed

About

Alwin D. R. Huitema is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alwin D. R. Huitema has authored 552 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Oncology, 120 papers in Pulmonary and Respiratory Medicine and 117 papers in Molecular Biology. Recurrent topics in Alwin D. R. Huitema's work include Cancer Treatment and Pharmacology (79 papers), HIV/AIDS drug development and treatment (58 papers) and Pharmacogenetics and Drug Metabolism (55 papers). Alwin D. R. Huitema is often cited by papers focused on Cancer Treatment and Pharmacology (79 papers), HIV/AIDS drug development and treatment (58 papers) and Pharmacogenetics and Drug Metabolism (55 papers). Alwin D. R. Huitema collaborates with scholars based in Netherlands, United States and Germany. Alwin D. R. Huitema's co-authors include Jos H. Beijnen, Jan H.M. Schellens, Hilde Rosing, Sjoerd Rodenhuis, Ron J. Keizer, Neeltje Steeghs, Milly E. de Jonge, Jan W. Mulder, Remy B. Verheijen and Thomas P. C. Dorlo and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alwin D. R. Huitema

531 papers receiving 12.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

2010 558 citations Ron J. Keizer, Alwin D. R. Huitema et al. Clinical Pharmacokinetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alwin D. R. Huitema Netherlands	56	4.3k	2.9k	2.0k	2.0k	1.5k	552	12.9k
Hilde Rosing Netherlands	56	6.7k 1.6×	4.6k 1.6×	1.5k 0.8×	997 0.5×	1.5k 1.0×	422	13.3k
Henk‐Jan Guchelaar Netherlands	63	4.6k 1.1×	4.1k 1.4×	1.9k 1.0×	551 0.3×	1.9k 1.3×	452	15.7k
Klemens Budde Germany	66	2.1k 0.5×	2.8k 1.0×	2.2k 1.1×	1.2k 0.6×	1.8k 1.3×	610	17.7k
Frank M. Balis United States	64	3.8k 0.9×	3.6k 1.2×	2.4k 1.2×	1.8k 0.9×	1.5k 1.1×	313	12.4k
Raman Venkataramanan United States	57	3.3k 0.8×	2.5k 0.9×	711 0.4×	1.9k 1.0×	3.6k 2.4×	362	15.3k
Peter C. Adamson United States	59	2.7k 0.6×	3.5k 1.2×	2.2k 1.1×	689 0.4×	2.1k 1.4×	238	11.3k
Merrill J. Egorin United States	66	5.5k 1.3×	5.9k 2.0×	2.2k 1.1×	500 0.3×	567 0.4×	380	14.2k
Elke Schaeffeler Germany	52	3.3k 0.8×	2.8k 1.0×	530 0.3×	724 0.4×	2.0k 1.4×	181	9.6k
Laurent A. Décosterd Switzerland	50	1.6k 0.4×	1.8k 0.6×	665 0.3×	3.8k 1.9×	1.2k 0.8×	270	10.1k
Ron H.J. Mathijssen Netherlands	66	7.2k 1.7×	5.1k 1.8×	3.5k 1.8×	336 0.2×	1.4k 0.9×	453	14.3k

Countries citing papers authored by Alwin D. R. Huitema

Since Specialization

Citations

This map shows the geographic impact of Alwin D. R. Huitema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alwin D. R. Huitema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alwin D. R. Huitema more than expected).

Fields of papers citing papers by Alwin D. R. Huitema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alwin D. R. Huitema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alwin D. R. Huitema. The network helps show where Alwin D. R. Huitema may publish in the future.

Co-authorship network of co-authors of Alwin D. R. Huitema

This figure shows the co-authorship network connecting the top 25 collaborators of Alwin D. R. Huitema. A scholar is included among the top collaborators of Alwin D. R. Huitema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alwin D. R. Huitema. Alwin D. R. Huitema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoop, Esther Oomen‐de, C. Louwrens Braal, Gabe S. Sonke, et al.. (2025). Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer. ESMO Open. 10(3). 104290–104290. 1 indexed citations

Koolen, Stijn L.W., et al.. (2025). Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward. Therapeutic Drug Monitoring. 47(6). 713–720.

Groenland, Stefanie L., Sil Kordes, Andries M. Bergman, et al.. (2025). Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients. British Journal of Cancer. 132(7). 635–642. 1 indexed citations

Sundar, Shyam, Dinesh Mondal, Murari Lal Das, et al.. (2024). Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. Journal of Antimicrobial Chemotherapy. 79(7). 1547–1554. 1 indexed citations

Bocxlaer, Katrien Van, Hilde Rosing, Alwin D. R. Huitema, et al.. (2024). Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices. Journal of Chromatography B. 1250. 124377–124377.

Huitema, Alwin D. R., et al.. (2024). Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials. Journal of Oncology Pharmacy Practice. 31(8). 1199–1209. 1 indexed citations

Beijnen, Jos H., et al.. (2024). Early Prediction and Impact Assessment of CYP3A4-Related Drug-Drug Interactions for Small-Molecule Anticancer Drugs Using Human-CYP3A4-Transgenic Mouse Models. Drug Metabolism and Disposition. 52(11). 1217–1223.

Krens, Stefanie D., Stefan Böhringer, Ingrid M.E. Desar, et al.. (2024). Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. British Journal of Clinical Pharmacology. 91(2). 297–305. 1 indexed citations

Huitema, Alwin D. R., Jourik A. Gietema, Jos H. Beijnen, et al.. (2024). Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors. PLoS ONE. 19(11). e0312994–e0312994. 1 indexed citations

10.

Beijnen, Jos H., et al.. (2023). The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib. Clinical and Translational Science. 16(12). 2557–2564. 2 indexed citations

11.

Janssen, Julie M., Kristel Van Calsteren, Thomas P. C. Dorlo, et al.. (2021). Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clinical Pharmacokinetics. 60(6). 775–784. 18 indexed citations

12.

Schmidt, Keith T., Cindy H. Chau, Jonathan D. Strope, et al.. (2021). Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. Molecular Cancer Therapeutics. 20(5). 915–924. 18 indexed citations

13.

Groenendaal, Floris, Marcel P. H. van den Broek, Carin M. A. Rademaker, et al.. (2019). Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia. PLoS ONE. 14(2). e0211910–e0211910. 23 indexed citations

14.

Langenhorst, Jurgen, Charlotte van Kesteren, Erik M. van Maarseveen, et al.. (2019). Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Advances. 3(14). 2179–2187. 45 indexed citations

15.

Suleiman, Ahmed A., et al.. (2016). Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. European Journal of Clinical Pharmacology. 72(6). 645–653. 24 indexed citations

16.

Henricks, Linda M., Jan H.M. Schellens, Alwin D. R. Huitema, & Jos H. Beijnen. (2015). The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. 41(10). 859–867. 73 indexed citations

17.

Jager, Nynke G L, Rutger H.T. Koornstra, Andrew Vincent, et al.. (2013). Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer. 13(1). 612–612. 18 indexed citations

18.

Wildeman, Maarten A., Zlata Novalić, Sandra A.W.M. Verkuijlen, et al.. (2012). Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors. Clinical Cancer Research. 18(18). 5061–5070. 73 indexed citations

19.

Dorlo, Thomas P. C., P. P. A. M. van Thiel, Alwin D. R. Huitema, et al.. (2008). Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients. Antimicrobial Agents and Chemotherapy. 52(8). 2855–2860. 118 indexed citations

20.

Crommentuyn, Kristel M. L., Hilde Rosing, M. J. X. Hillebrand, Alwin D. R. Huitema, & Jos H. Beijnen. (2004). Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography B. 804(2). 359–367. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact